FY2027 Earnings Forecast for EVAX Issued By HC Wainwright

Evaxion Biotech A/S (NASDAQ:EVAX) – Analysts at HC Wainwright decreased their FY2027 earnings per share estimates for shares of Evaxion Biotech A/S in a report issued on Wednesday, April 2nd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.12 per share for the year, down from their prior forecast of $0.13. HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Evaxion Biotech A/S’s FY2028 earnings at $0.05 EPS and FY2029 earnings at $0.09 EPS.

Evaxion Biotech A/S (NASDAQ:EVAX) last issued its quarterly earnings results on Tuesday, April 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.19. The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $1.66 million.

Separately, Lake Street Capital lowered their price objective on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th.

Evaxion Biotech A/S Trading Down 10.7 %

Shares of NASDAQ EVAX opened at $1.51 on Friday. The company has a market cap of $1.77 million, a price-to-earnings ratio of -1.04 and a beta of -0.25. Evaxion Biotech A/S has a fifty-two week low of $1.50 and a fifty-two week high of $22.05. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. The business’s 50 day moving average price is $2.30 and its 200-day moving average price is $6.80.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC acquired a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S at the end of the most recent reporting period. 11.04% of the stock is owned by hedge funds and other institutional investors.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.